Hologic, Inc. (NASDAQ:HOLX) Shares Sold by Vanguard Group Inc.

Vanguard Group Inc. decreased its holdings in shares of Hologic, Inc. (NASDAQ:HOLX) by 0.2% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 26,893,638 shares of the medical equipment provider’s stock after selling 58,726 shares during the period. Vanguard Group Inc. owned approximately 11.91% of Hologic worth $1,938,762,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. General Partner Inc. acquired a new position in Hologic during the fourth quarter worth $26,000. Groupama Asset Managment boosted its position in shares of Hologic by 9.9% during the 3rd quarter. Groupama Asset Managment now owns 33,177 shares of the medical equipment provider’s stock worth $27,000 after purchasing an additional 2,999 shares in the last quarter. Venturi Wealth Management LLC grew its stake in shares of Hologic by 156.3% during the 4th quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider’s stock worth $31,000 after purchasing an additional 261 shares during the period. EverSource Wealth Advisors LLC increased its holdings in shares of Hologic by 79.8% in the 4th quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider’s stock valued at $42,000 after purchasing an additional 260 shares in the last quarter. Finally, Smartleaf Asset Management LLC lifted its stake in shares of Hologic by 36.9% in the fourth quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider’s stock valued at $43,000 after purchasing an additional 159 shares during the period. 94.73% of the stock is owned by hedge funds and other institutional investors.

Hologic Stock Up 1.1 %

HOLX stock opened at $61.48 on Thursday. The company has a 50 day moving average price of $65.56 and a two-hundred day moving average price of $73.57. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.78 and a current ratio of 3.49. The stock has a market capitalization of $13.80 billion, a P/E ratio of 19.39, a PEG ratio of 2.14 and a beta of 0.97. Hologic, Inc. has a one year low of $60.34 and a one year high of $84.67.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. As a group, sell-side analysts expect that Hologic, Inc. will post 4.28 EPS for the current year.

Analyst Ratings Changes

HOLX has been the subject of a number of research analyst reports. Stephens reaffirmed an “overweight” rating and issued a $84.00 target price on shares of Hologic in a report on Thursday, February 6th. Morgan Stanley dropped their price objective on Hologic from $84.00 to $82.00 and set an “equal weight” rating for the company in a research note on Monday, January 13th. Needham & Company LLC downgraded Hologic from a “buy” rating to a “hold” rating and set a $90.00 target price on the stock. in a research report on Monday, February 3rd. BNP Paribas upgraded Hologic to a “strong-buy” rating in a research report on Tuesday, December 10th. Finally, Wolfe Research began coverage on shares of Hologic in a research report on Friday, December 13th. They issued a “peer perform” rating on the stock. Eleven research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $84.62.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.